STOCK TITAN
  1. Home
  2. News
  3. RHHBY

Roche Holding AG - RHHBY STOCK NEWS

Welcome to our dedicated news page for Roche Holding (Ticker: RHHBY), a resource for investors and traders seeking the latest updates and insights on Roche Holding.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Roche Holding's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Roche Holding's position in the market.

News
CHMP recommends Roche’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA)
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
none
-
News
New clinical and real-world data for Roche’s Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
none
-
News
New Clinical and Real-World Data for Genentech’s Vabysmo at ASRS Reveal Improved Outcomes for People With Two Leading Causes of Vision Loss
Rhea-AI Summary
Genentech, a member of the Roche Group, will present data on its ophthalmology portfolio, including Vabysmo, at the 2023 ASRS Annual Meeting. The data highlight the efficacy of Vabysmo in treating wet AMD and DME, with positive anatomical outcomes and real-world evidence supporting its use. Vabysmo is currently approved in over 70 countries and has distributed over one million doses globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
none
News
Roche to showcase next-generation diagnostic solutions at the American Association of Clinical Chemistry 2023 Clinical Lab Expo
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none
-
News
Positive Phase III results for Roche’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
clinical trial
-
News
Positive Phase III Results for Genentech’s Ocrevus (ocrelizumab) Twice a Year, 10-Minute Subcutaneous Injection in Patients With Multiple Sclerosis
Rhea-AI Summary
Genentech, a member of the Roche Group, announced that the Phase III OCARINA II trial evaluating Ocrevus as a subcutaneous injection met its primary and secondary endpoints. The injection was shown to be non-inferior to Ocrevus given by intravenous infusion and was comparable in controlling MRI lesion activity. The safety profile of the injection was consistent with that of the IV infusion. The 10-minute injection has the potential to expand the usage of Ocrevus in MS centers without IV infrastructure or with IV capacity limitations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
clinical trial
News
European Commission approves Roche’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma
Rhea-AI Summary
Roche's Columvi receives conditional marketing authorization in Europe for the treatment of relapsed or refractory diffuse large B-cell lymphoma. Columvi is the first CD20xCD3 T-cell-engaging bispecific antibody available in Europe for this indication. It has the potential to change the current standard of care in DLBCL by inducing early and long-lasting responses and providing a treatment-free period. The approval is based on positive results from a pivotal study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
none
-
News
Four-year follow up data for Roche’s Evrysdi show continued increase in number of children with a severe form of spinal muscular atrophy (SMA) able to sit, stand and walk
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.24%
Tags
none
-
News
Four-Year Follow-Up Data for Genentech’s Evrysdi Show Continued Increase in Number of Children With a Severe Form of Spinal ​Muscular ​Atrophy (SMA)​ Able to Sit, Stand and Walk
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.24%
Tags
none
News
Roche receives FDA clearance for additional Alzheimer's disease Cerebrospinal Fluid (CSF) assays, supporting timely diagnosis and treatment decision-making
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.61%
Tags
clinical trial
Stock RHHBY logo
Roche Holding AG

OTC:RHHBY

RHHBY Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

RHHBY Stock Data

199.10B
727.48M
0.15%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Switzerland
Basel